Keyword: Gemphire Therapeutics
The move comes as NeuroBo gears up to start a phase 3 trial of nerve growth factor therapy NB-01 in patients with diabetic neuropathic pain.
Curis moves up COO as CEO departs; Merck scraps mandatory retirement age to keep CEO Frazier; and Bayer’s Americas pharma head to be CEO at Selecta.
Gemphire is cutting its staff in a bid to cut costs after the FDA requested more preclinical data for its only drug, gemcabene.
Gemphire is halting a midphase trial testing gemcabene in pediatric nonalcoholic fatty liver disease because some patients’ disease got worse.